PROX1 and gastric cancer: The findings showed that the expression of PROX1 was not related to 1-year, 3-year, and 5-year OS of GC patients (1-year OS: OR: 0.908, 95% CI 0.631–1.306, P = 0.602; 3-year OS: OR: 1.234, 95% CI 0.482–3.160, P = 0.661; 4-year OS: OR: 0.853, 95% CI 0.266–2.736, P = 0.790) (Fig. 8).